Xiamen C&D Emerging Industry Equity Investment
Xiamen, Fujiancndem.com
Overview
Xiamen C&D Emerging Industry Equity Investment is the professional equity investment arm of the Fortune 500 company C&D Group, focusing on investments in emerging industries such as healthcare, advanced manufacturing, and TMT/consumption.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Vivacta Biotechnology (Shanghai) Co., Ltd. | Apr 2026 | Series A | Co-investor |
| IMPACT Therapeutics | Apr 2024 | Series D Extension | Co-investor |
| Zelostech | Feb 2024 | Series A | Co-investor |
| Sanegene Bio | Dec 2023 | Series A Extension | Co-investor |
| Zhejiang BangEr Orthopedic Hospital Group | Nov 2023 | Private Equity | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
